Pyrroloquinoline Bradykinin antagonist
    5.
    发明授权
    Pyrroloquinoline Bradykinin antagonist 失效
    吡咯喹啉缓激肽拮抗剂

    公开(公告)号:US5288725A

    公开(公告)日:1994-02-22

    申请号:US961589

    申请日:1992-10-15

    IPC分类号: C07D471/04 A61K31/44

    CPC分类号: C07D471/04

    摘要: A pyrroloquinoline compound of the following formula is disclosed: ##STR1## wherein H,C.sub.1-6 alkyl,R.sup.1 is: ##STR2## wherein R is H, C.sub.1-10 alkyl, or C.sub.1-6 alkyloxycarbonyl; R.sup.2 is:H,C.sub.1-6 alkyl, ##STR3## wherein R.sup.5 is C.sub.1-10 alkyl, aryl, or aryl C.sub.1-10 alkyl; R.sup.3 is:(CH.sub.2).sub.n NHR wherein R is H, C.sub.1-6 alkyl, or C.sub.1-6 alkyloxycarbonyl; ##STR4## R.sup.4 is: H,C.sub.1-6 alkyl,C.sub.1-6 alkyloxycarbonyl,RCH.sub.2 --, wherein R is H, C.sub.1-6 alkyl or aryl, or ##STR5## X is O, or NR.sup.6 wherein R.sup.6 is equal to H or C.sub.1-6 alkyl and n is an integer from 1-3.The compounds of the invention exhibit bradykinin antagonist activity as well as activity with .alpha.-adrenergic, histaminergic, and muscarinic receptors.

    摘要翻译: 公开了下式的吡咯并喹啉化合物:其中H,C 1-6烷基,R 1是:其中R是H,C 1-10烷基或C 1-6 烷氧基羰基 R 2是:H,C 1-6烷基,其中R 5是C 1-10烷基,芳基或芳基C 1-10烷基; R3是:(CH2)nNHR,其中R是H,C1-6烷基或C1-6烷氧基羰基; R 4是:H,C 1-6烷基,C 1-6烷氧基羰基,RCH 2 - ,其中R是H,C 1-6烷基或芳基,或者X是O或NR 6,其中R 6相同 至H或C 1-6烷基,n为1-3的整数。 本发明的化合物表现出缓激肽拮抗剂活性以及具有α-肾上腺素能,组胺能和毒蕈碱受体的活性。

    Cyclic hexapeptides
    7.
    发明授权
    Cyclic hexapeptides 失效
    循环下一个

    公开(公告)号:US4108987A

    公开(公告)日:1978-08-22

    申请号:US832501

    申请日:1977-09-12

    摘要: Synthetic novel cyclic hexapeptides having the structure:Cyclo[(N-alkylamino acid)-X-(N-alkylamino acid)'-X-(N-alkylamino acid)"-X]wherein (N-alkylamino acid), (N-alkylamino acid)' and (N-alkylamino acid)" have the structure: ##STR1## wherein R.sup.1 is a lower alkyl group having 1 to 3 carbon atoms and R.sup.2 is hydrogen and methyl or R.sup.1 and R.sup.2 are --CH.sub.2 --N, n being an integer 2 or 3, and form a 4- or 5- membered ring; and X is D- or L-Ala, D- or L-Phe, D- or L-Leu, D- or L-p-halophenylalanyl or D- or L-p-nitrophenylalanyl, with the proviso that when R.sup.1 is methyl and R.sup.2 is hydrogen, X is not D-Ala are prepared. Oral administration of these cyclic peptides improves the digestive efficiency of certain herbivorous animals.